DOCSLIB.ORG

Clinical Protocol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Clinical Protocol Protocol 15-001CA Nasal CO2 CLINICAL PROTOCOL Protocol No. 15-001CA Title: An Open Label, Pilot Study Evaluating the Efficacy and Safety of the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache Version: Original 10 March 2015 Amendment 1 30 November 2015 Amendment 2 28 April 2016 Sponsor: Dr. Timothy Smith Clinvest Research, LLC. 3805 South Kansas Expressway, Suite B Springfield, MO 65807 Phone: 417-883-7889 Approval: Investigator Printed Name Signature _________________________________ Date CONFIDENTIAL This document contains proprietary and confidential information about Nasal CO2 Dispenser. Acceptance of this document constitutes agreement by the recipient that no previously unpublished information contained herein will be published or disclosed without the prior written approval of the manufacturer, Capnia, Inc. (Capnia), with the exception that this document may be disclosed to study personnel under your supervision who need to know the contents for conducting the study and appropriate Institutional Review Boards (IRBs)/Ethics Committees (ECs) under the condition that the personnel have agreed to keep this information confidential. The foregoing shall not apply to disclosure required by governmental regulations or laws; however, Capnia shall be promptly notified of any such disclosure. Protocol 15-001CA Nasal CO2 TABLE OF CONTENTS CLINICAL PROTOCOL ..............................................................................................................1 1.0 STUDY SYNOPSIS ..............................................................................................................6 2.0 LIST OF ABBREVIATIONS ............................................................................................12 3.0 BACKGROUND .................................................................................................................14 3.1 Investigational Product ...............................................................................................14 3.2 Cluster Headache ........................................................................................................14 3.3 Non-Clinical and Clinical Data ..................................................................................15 3.3.1 In Vitro Non-Clinical Evaluations ................................................................15 3.3.2 In Vivo Non-Clinical Evaluations ................................................................15 3.3.3 Clinical Evaluation in Healthy Volunteers ...................................................15 3.3.4 Clinical Evaluations in Acute Migraine .......................................................16 3.3.4.1 CH-2000-02 (Migraine Phase 1) ................................................16 3.3.4.2 CH-2002-01 (Migraine Phase 2a) ..............................................17 3.3.4.3 CH-2004-03 (Migraine Phase 2b) ..............................................17 3.3.4.4 C112 (Mild Headache Study) .....................................................18 3.3.4.5 C113 (Phase 3, Moderate to Severe Migraine Study) ................18 3.3.5 Clinical Evaluations in Allergic Rhinitis .....................................................19 3.3.5.1 SAR-2005 (Seasonal Allergic Rhinitis Single-Dose Study) ......19 3.3.5.2 C211 (Perennial Allergic Rhinitis Single-Dose Study) ..............20 3.3.5.3 C213 (Perennial Allergic Rhinitis Multi-Dose Study) ...............20 3.3.5.4 C215 (Seasonal Allergic Rhinitis Multi-Dose Study) ................21 3.3.5.5 C216 (Phase 2, Seasonal Allergic Rhinitis) ...............................21 3.3.5.6 C218 (Phase 2, Seasonal Allergic Rhinitis) ...............................22 3.3.5.7 RH01910 (Phase 2, Nasal Congestion) ......................................22 3.3.6 Clinical Evaluation in Temporomandibular Disorders ................................23 3.4 Risk/Benefits ...............................................................................................................23 3.5 Dose Rationale ............................................................................................................23 3.6 Trial Conduct ..............................................................................................................24 3.7 Population ...................................................................................................................24 4.0 TRIAL OBJECTIVES .......................................................................................................24 4.1 Primary Objective .......................................................................................................24 4.2 Secondary Objectives .................................................................................................24 2 Confidential Information 28 April 2016 Protocol 15-001CA Nasal CO2 5.0 TRIAL DESIGN .................................................................................................................24 5.1 Primary, Secondary, and Exploratory Endpoints .......................................................25 5.1.1 Primary Endpoint .........................................................................................25 5.1.2 Secondary Endpoints ....................................................................................25 5.2 Study Treatment ..........................................................................................................26 5.2.1 Dose Description ..........................................................................................26 5.2.1.1 Nasal CO2 Dispensers .................................................................26 5.2.2 Packaging and Labeling ...............................................................................26 5.2.3 Storage and Handling ...................................................................................27 5.3 Duration ......................................................................................................................27 5.4 Discontinuation ...........................................................................................................27 5.5 Investigational Product Accountability ......................................................................28 5.6 Data Identification ......................................................................................................28 6.0 SELECTION AND WITHDRAWAL OF SUBJECTS ...................................................29 6.1 Inclusion Criteria ........................................................................................................29 6.2 Exclusion Criteria .......................................................................................................29 6.3 Subject Withdrawal ....................................................................................................30 6.4 Screen Failures ............................................................................................................31 7.0 TREATMENT OF SUBJECTS ........................................................................................31 7.1 Treatments to be Administered ...................................................................................31 7.1.1 Nasal CO2 Dispenser ....................................................................................31 7.2 Medication ..................................................................................................................32 7.2.1 Concomitant Medication ..............................................................................32 7.2.2 Medications Not Permitted ...........................................................................32 7.2.3 Rescue Medication .......................................................................................33 7.3 Monitoring for Subject Compliance ...........................................................................33 8.0 STUDY PROCEDURES ....................................................................................................33 8.1 Description of Study Procedures and Assessments ....................................................33 8.1.1 Informed Consent .........................................................................................33 8.1.2 Medical History, Medications and Demographics .......................................34 8.1.3 Physical Examination ...................................................................................34 8.1.4 Vital Signs ....................................................................................................34 8.1.5 Nasal Mucosal Examination .........................................................................34 8.1.6 Urine Pregnancy Test ...................................................................................35 3 Confidential Information 28 April 2016 Protocol 15-001CA Nasal CO2 8.1.7 Enrollment ....................................................................................................35 8.1.8 Training ........................................................................................................35 8.1.9 Subject Diary and Assessments ....................................................................35 8.1.10 Treatment of Cluster Headaches ..................................................................36 8.1.11 Adverse Events .............................................................................................36 8.1.12 Concomitant Medications / Procedures ........................................................37 8.1.13 Telephone Contact ........................................................................................37
Load more

Recommended publications
  • Does the Reduction of Inferior Turbinate Affect Lower Airway Functions?
    Braz J Otorhinolaryngol. 2019;85(1):43---49 Brazilian Journal of OTORHINOLARYNGOLOGY www.bjorl.org ORIGINAL ARTICLE Does the reduction of inferior turbinate affect lower ଝ airway functions? a,∗ a b a Ozlem Unsal , Mehtap Ozkahraman , Mufide Arzu Ozkarafakili , Meltem Akpinar , a a a Arzu Yasemin Korkut , Senem Kurt Dizdar , Berna Uslu Coskun a Sisli Hamidiye Etfal Training and Research Hospital, Clinic of Otorhinolaryngology, Istanbul, Turkey b Sisli Hamidiye Etfal Training and Research Hospital, Clinic of Pulmonary Diseases, Istanbul, Turkey Received 31 July 2017; accepted 16 October 2017 Available online 6 November 2017 KEYWORDS Abstract Acoustic rhinometry; Introduction: Although the nose and lungs are separate organs, numerous studies have reported Turbinates; that the entire respiratory system can be considered as a single anatomical and functional unit. Hypertrophy; The upper and lower airways affect each other either directly or through reflex mechanisms. Spirometry; Objective: In this study, we aimed to evaluate the effects of the radiofrequency ablation of Respiratory system persistent inferior turbinate hypertrophy on nasal and pulmonary function. Methods: Twenty-seven patients with bilateral persistent inferior turbinate hypertrophy with- out septal deviation were included in this study. All of the patients were evaluated using anterior rhinoscopy, nasal endoscopy, acoustic rhinometry, a visual analogue scale, and flow-sensitive spirometry on the day before and 4 months after the radiofrequency ablation procedure. Results: The post-ablation measurements revealed that the inferior turbinate ablation caused an increase in the mean cross-sectional area and volume of the nose, as well as in the forced expiratory volume in 1 s, forced vital capacity, and peak expiratory flow of the patients.
    [Show full text]
  • Heated and Humidified High-Flow Oxygen Therapy Reduces Discomfort During Hypoxemic Respiratory Failure
    Heated and Humidified High-Flow Oxygen Therapy Reduces Discomfort During Hypoxemic Respiratory Failure Elise Cuquemelle MD, Tai Pham MD, Jean-Franc¸ois Papon MD PhD, Bruno Louis PhD, Pierre-Eric Danin MD, and Laurent Brochard MD PhD BACKGROUND: Non-intubated critically ill patients are often treated by high-flow oxygen for acute respiratory failure. There is no current recommendation for humidification of oxygen devices. METHODS: We conducted a prospective randomized trial with a final crossover period to compare nasal airway caliber and respiratory comfort in patients with acute hypoxemic respiratory failure receiving either standard oxygen therapy with no humidification or heated and humidified high- flow oxygen therapy (HHFO2) in a medical ICU. Nasal airway caliber was measured using acoustic rhinometry at baseline, after 4 and 24 hours (H4 and H24), and 4 hours after crossover (H28). Dryness of the nose, mouth, and throat was auto-evaluated and assessed blindly by an otorhinolaryngologist. After the crossover, the subjects were asked which system they preferred. RESULTS: Thirty subjects completed the protocol and were analyzed. Baseline median oxygen flow was 9 and 12 L/min in the ؍ standard and HHFO2 groups, respectively (P .21). Acoustic rhinometry measurements showed no difference between the 2 systems. The dryness score was significantly lower in the HHFO2 group at H4 During the crossover period, dryness increased promptly .(004. ؍ and H24 (0 vs 8, P (007. ؍ vs 6, P 2) ؍ after switching to standard oxygen and decreased after switching to HHFO2 (P .008). Sixteen subjects ؍ (53%) preferred HHFO2 (P .01), especially those who required the highest flow of oxygen at admis- ؍ sion (P .05).
    [Show full text]
  • Subjective and Objective Improvement in Breathing After Rhinoplasty
    ORIGINAL ARTICLE ONLINE FIRST Subjective and Objective Improvement in Breathing After Rhinoplasty Richard A. Zoumalan, MD; Minas Constantinides, MD Objective: To determine whether rhinoplasty im- cedures undergone, including spreader grafts and alar bat- proves subjective and objective nasal patency. ten grafts, and on the absence of osteotomies. These groups had similar results. In patients with severe obstruction, Design: Retrospective study including subjective breath- all measured values improved more than any other sub- ing scores and acoustic rhinometry before and 6 to 9 group, including the MCA, which improved signifi- months after septorhinoplasty among a cohort of 31 pa- cantly by an average of 55%. Patients with normal pre- tients. We used a paired t test to analyze the difference operative MCA values did not experience any significant between preoperative and postoperative values. changes except for an anterior shift in MCA. Setting: Academic medical center. Conclusions: Septorhinoplasty increases nasal vol- ume, decreases nasal resistance, and advances the MCA Patients: Patients undergoing septorhinoplasty with po- anteriorly. These changes coexist with subjective im- tassium titanyl phosphate laser turbinate reduction at a single institution. provements in nasal patency, which suggests that this new anatomic configuration creates a positive outcome on na- Results: The mean subjective breathing scores im- sal airflow. Spreader grafts do not increase the MCA sig- proved significantly, with an overall improvement of 38%. nificantly. Patients with preoperative severe obstruc- The overall mean volume increased and the overall re- tion have the best overall improvement, whether measured sistance decreased, but the changes were significant only subjectively or objectively. on the right side.
    [Show full text]
  • Alteraes Na Mucosa Nasal Provocadas Pela Presso Atmosfrica, Oxignio E
    ALTERAÇÕES NA MUCOSA NASAL PROVOCADAS PELA PRESSÃO ATMOSFÉRICA, OXIGÉNIO E OUTROS FACTORES PAULO SÉRGIO ALVES VERA-CRUZ PINTO Dissertação de doutoramento em Ciências Médicas 2009 PAULO SÉRGIO ALVES VERA-CRUZ PINTO ALTERAÇÕES NA MUCOSA NASAL PROVOCADAS PELA PRESSÃO ATMOSFÉRICA, OXIGÉNIO E OUTROS FACTORES Dissertação de candidatura ao grau de Doutor em Ciências Médicas, submetida ao Instituto de Ciências Biomédicas de Abel Salazar da Universidade do Porto. Orientador – Professor Doutor Carlos Zagalo, professor do Instituto de Ciências da Saúde Egas Moniz. Co-Orientador – Professor Doutor Artur Águas, professor catedrático do Instituto de Ciências Biomédicas de Abel Salazar da Universidade do Porto. Porto 2009 2 À Carla, ao Gonçalo e ao Bernardo 3 4 “Try and leave this world a little better than you found it and when your turn come to die, you can die happy in feeling that at any rate you have not wasted your time but have done your best.” Lord Robert Baden-Powell's Last Message to Scouts, 1941 5 6 ÍNDICE Preceitos legais ...................................................................................................................9 Agradecimentos.................................................................................................................10 INTRODUÇÃO...................................................................................................................12 1- Anatomia das Fossas Nasais no Humano ................................................................12 2 - Anatomia das Fossas Nasais no Rato .....................................................................14
    [Show full text]
  • R.A.L.E. Reference Collection Updated November 2007 1. Beck, R
    R.A.L.E. Reference Collection updated November 2007 1. Beck, R., N. Elias, S. Shoval, N. Tov, G. Talmon, S. Godfrey, and L. Bentur. 2007. Computerized acoustic assessment of treatment efficacy of nebulized epinephrine and albuterol in RSV bronchiolitis. BMC.Pediatr. 7:22.:22. Abstract: AIM: We evaluated the use of computerized quantification of wheezing and crackles compared to a clinical score in assessing the effect of inhaled albuterol or inhaled epinephrine in infants with RSV bronchiolitis. METHODS: Computerized lung sounds analysis with quantification of wheezing and crackles and a clinical score were used during a double blind, randomized, controlled nebulized treatment pilot study. Infants were randomized to receive a single dose of 1 mgr nebulized l-epinephrine or 2.5 mgr nebulized albuterol. Computerized quantification of wheezing and crackles (PulmoTrack) and a clinical score were performed prior to, 10 minutes post and 30 minutes post treatment. Results were analyzed with Student's t-test for independent samples, Mann-Whitney U test and Wilcoxon test. RESULTS: 15 children received albuterol, 12 received epinephrine. The groups were identical at baseline. Satisfactory lung sounds recording and analysis was achieved in all subjects. There was no significant change in objective quantification of wheezes and crackles or in the total clinical scores either within the groups or between the groups. There was also no difference in oxygen saturation and respiratory distress. CONCLUSION: Computerized lung sound analysis is feasible in young infants with RSV bronchiolitis and provides a non-invasive, quantitative measure of wheezing and crackles in these infants 2. Beeton, R. J., I.
    [Show full text]
  • Clinical Research Faculty Thomas B
    Clinical Research Faculty Thomas B. Casale, M.D. Roger W. Fox, M.D. [email protected] [email protected] • Director, Clinical & Translational Research • Professor of Medicine, Pediatrics, and Public Health • Professor of Medicine • Board certified in Internal Medicine and Allergy and Immunology • Board certified in Internal Medicine and Allergy and Immunology Mark C. Glaum, M.D., Ph.D. Richard F. Lockey, M.D. [email protected] [email protected] • Associate Professor of Medicine and Pediatrics • Associate Director, Clinical Research & Translational Research • Board certified in Internal Medicine and Allergy and Immunology • Director, Division of Allergy and Clinical Immunology • Distinguished University Health Professor • Professor of Medicine, Pediatrics, and Public health Basic Research Faculty • Joy McCann Culverhouse Chair of Allergy and Immunology • Board Certified in Internal Medicine and Allergy and Immunology Michael Teng, Ph.D. University of • Associate Professor of Medicine, Molecular Medicine and Pediatrics Dennis K. Ledford, M.D. South Florida [email protected] Narasaiah Kolliputi, Ph.D. • Professor of Medicine and Pediatrics • Associate Professor of Medicine, Molecular Medicine and Pediatrics Division of Allergy and Immunology • Mabel and Ellsworth Simmons Professor Allergy and Immunology • Board certified in Internal Medicine, Allergy and Immunology, and Rheumatology Jia Wang, Ph.D. Clinical and Translational Research Unit • Assistant Professor of Medicine, Molecular Medicine and Pediatrics The Joy McCann
    [Show full text]
  • Functional Rhinoplasty
    Functional Rhinoplasty David W. Kim, MDa,b,*, Krista Rodriguez-Bruno, MDa KEYWORDS Functional rhinoplasty Internal nasal valve External nasal valve Upper lateral cartilages Lower lateral cartilages Over the past couple of decades, there has been an evident in the last 20 years, during which the field increasingly sophisticated understanding of the of facial plastic surgery has experienced an evolu- pathophysiology underlying fixed nasal obstruction. tion in its surgical philosophy. Previously, empha- In the past, submucous resection of the quadrangu- sis had been placed on reductive techniques that lar cartilage, septoplasty, and inferior turbinate achieved short-term, cosmetic goals, often used reduction procedures were the predominant work- at the expense of nasal framework stability. With horse techniques to address fixed nasal obstruction. expanded understanding of the structural and dy- Although these procedures continue to be a vital namic roles of the nasal scaffold, an increased ap- part of nasal airway surgery, they do not directly preciation has developed for the consequences address other types of anatomic obstruction, such that surgical modifications have on dynamic nasal as insufficiency of the lateral nasal wall, pinching of airflow.1,2 Toriumi and coworkers3 exemplified this the upper lateral cartilage (ULC), or alar collapse. trend and focused on a conservative surgical Problems in these areas are part of the large group approach aimed at stabilizing and reorienting the of disorders lumped into the term ‘‘nasal valve insuf- nasal anatomic structures instead of reducing ficiency.’’ To treat these problems, surgeons have them, to ensure long-term cosmetic results while adopted a greater range of operative techniques.
    [Show full text]
  • Methods of Airway Resistance Assessment
    PRACA ORYGINALNAREVIEW Tomasz Urbankowski, Tadeusz Przybyłowski Department of Internal Medicinie, Pneumonology and Allergy, Medical University of Warsaw, Poland Methods of airway resistance assessment The authors declare no financial disclosure Abstract Airway resistance is the ratio of driving pressure to the rate of the airflow in the airways. The most frequent methods used to measure airway resistance are whole-body plethysmography, the interrupter technique and the forced oscillation technique. All these methods allow to measure resistance during respiration at the level close to tidal volume, they do not require forced breathing manoeuvres or deep breathing during measurement. The most popular method for measuring airway resistance is whole-body plethysmography. The results of plethysmography include among others the following parameters: airway resistance (Raw), airway conductance (Gaw), specific airway resistance (sRaw) and specific airway conductance (sGaw). The interrupter technique is based on the assumption that at the mo- ment of airway occlusion, air pressure in the mouth is equal to the alveolar pressure . In the forced oscillation technique (FOT), airway resistance is calculated basing on the changes in pressure and flow caused by air vibration. The methods for measurement of airway resistance that are described in the present paper seem to be a useful alternative to the most common lung function test — spirome- try. The target group in which these methods may be widely used are particularly the patients who are unable to perform spirometry. Pneumonol Alergol Pol 2016; 84: 134–141 Key words: lung function tests, airway resistance, plethysmography Introduction its characteristics and shape of the airways is complex [1]. Figure 1 illustrates contribution of Airway resistance is defined as the ratio separate components to total airway resistance.
    [Show full text]
  • The Expansion of Autologous Adipose-Derived Stem Cells in Vitro
    Xu et al. Cell Biosci (2015) 5:54 DOI 10.1186/s13578-015-0045-7 RESEARCH Open Access The expansion of autologous adipose‑derived stem cells in vitro for the functional reconstruction of nasal mucosal tissue Xiao Xu, Liang Li, Cheng Wang, Yang Liu, Chong Chen, Junling Yan, Hong Ding and Su‑yang Tang* Abstract Background: It is established that adipose-derived stem cells (ADSCs) produce and secrete cytokines/growth fac‑ tors that antagonize mucosal injury. However, the exact molecular basis underlying the treatment effects exerted by ADSCs is ill understood, and whether ADSCs cooperate with adipose tissue particles to improve mucosal function in patients with empty nose syndrome (ENS) has not been explored. We investigated the impact of ADSCs on nasal mucosa, the associated mechanisms, and their use in the treatment of patients with ENS. Results: The nasal endoscope and mucociliary clearance assessments were significantly improved (P < 0.05) in patients with (n 28) and without (n 2) a rudimentary turbinate that received ADSCs combined with fat granules transplantation. =Patients experienced a= significant improvement in nasal obstruction and nasal mucociliary clear‑ ance after nasal turbinate angioplasty (P < 0.05). H&E staining, Masson’s staining, and AB-PAS staining confirmed that inflammation was significantly reduced, collagenous fibers became aligned, fewer deposits were observed, and the mucosal proteins generated from caliciform cells increased following treatment. After a 14-day incubation period, ADSCs developed a polygonal cobblestone shape characteristic of human epithelial cells. Furthermore, immunohisto‑ chemical analysis revealed the presence of epithelial markers such as cytokeratin-7, and cytokeratin-19. Western blot analysis showed the presence of specific epithelial cell markers including cytokeratin-7, cytokeratin-14 and cytokera‑ tin-19 in these epithelial like cells (ELC); these markers had low expression levels of ADSCs.
    [Show full text]
  • Appendices A
    Appendices A. Search Strategy Table A-1. Search strategy for Key Question 1 Search terms Result "PEP therapy"[tiab] OR "PEP mask"[tiab] OR "Oscillating PEP"[tiab] OR "Chest Wall Oscillation"[mh] 2981 OR "postural drainage"[tiab] OR "Drainage, Postural"[mh] OR ((respiratory[tiab] OR lung[tiab] OR Lung[mh] OR chest[tiab]) AND ("Physical Therapy Modalities"[Mesh:NoExp] OR "physical therapy"[tiab] OR physiotherapy[tiab])) OR "HFCC"[tiab] OR ("high frequency"[tiab] AND chest[tiab] AND (compression[tiab] OR oscillation[tiab])) OR "intrapulmonary percussive ventilation"[tiab] OR Frequencer[tiab] OR "lung flute"[tiab] OR autogenic drainage[tiab] OR ACBT[tiab] OR "active cycle of breathing"[tiab] OR "cough assist"[tiab] OR "cough assistance"[tiab] OR "assisted cough"[tiab] OR "MI-E"[tiab] OR "mechanical insufflation-exsufflation"[tiab] OR "thoracic squeeze"[tiab] ((Positive-Pressure Respiration[mh] OR "positive expiratory pressure"[tiab] OR Flutter[tiab] OR 3696 Quake[tiab] OR Cornet[tiab] OR "RC-Cornet"[tiab] OR Acapella[tiab]OR Percussion[mh] OR percussion[tiab] OR percussing[tiab] OR Vibration[mh] OR vibration[tiab] OR oscillating[tiab] OR oscillation[tiab] OR Sound[mh] OR "sound waves"[tiab] OR Bronchoscopy[mh] OR Suction[mh] OR suction*[tiab] OR IPV[tiab] OR "Breathing Exercises"[mh] OR "non-drug"[tiab] OR "non- pharmacological"[tiab]) AND (Airway Obstruction/therapy[mh] OR "airway clearance"[tiab] OR "airway clearing"[tiab] OR "airway obstruction"[tiab] OR "airflow obstruction"[tiab] OR "lung clearance"[tiab] OR "lung clearing"[tiab] OR "sputum
    [Show full text]
  • Does Cosmetic Rhinoplasty Affect Nose Function?
    International Scholarly Research Network ISRN Otolaryngology Volume 2011, Article ID 615047, 6 pages doi:10.5402/2011/615047 Clinical Study Does Cosmetic Rhinoplasty Affect Nose Function? Seyed Behzad Pousti, Sam Touisserkani, Maryam Jalessi, Seyed Kamran Kamrava, Nader Sadigh, Ashkan Heshmatzade Behzadi, and Arash Arvin ENT-Head and Neck Research Center, Hazrat Rasoul Akram Hospital, Tehran University of Medical Sciences, Tehran 14455-364, Iran Correspondence should be addressed to Maryam Jalessi, [email protected] Received 19 June 2011; Accepted 21 July 2011 Academic Editors: W. Freysinger and M. P. Robb Copyright © 2011 Seyed Behzad Pousti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. To evaluate the changes in nasal dimensions of healthy Iranian volunteered for cosmetic rhinoplasty after surgery using acoustic rhinometry. Methods. Pre- and postoperative nasal dimension of 36 cases undergoing cosmetic rhinoplasty were compared using acoustic rhinometry (AR), and the measured variables were distance to first and second constriction (d1, d2), first and second minimal cross-sectional area (MCA1, 2), and volume. Results. Mean age (SD) of cases were 24.63 (4.4) years. Septoplasty was performed in 12 cases (33.3%). After surgery, bilateral d1 and both MCA2 decreased significantly, while significant increase was observed in MCA1 postoperatively using decongestant. Cases with septoplasty experienced more increase in MCA1 and less constriction in MCA2 postoperatively. In cases with rhinoplasty alone, they received benefit from double osteotomy in MCA1. In either group of rhinoplasty with and without septoplasty, placing a strut was beneficial for patients.
    [Show full text]
  • School Air Quality Related to Dry Cough, Rhinitis and Nasal Patency in Children
    Eur Respir J 2010; 35: 742–749 DOI: 10.1183/09031936.00016309 CopyrightßERS Journals Ltd 2010 School air quality related to dry cough, rhinitis and nasal patency in children M. Simoni*, I. Annesi-Maesano#, T. Sigsgaard", D. Norback+, G. Wieslander+, W. Nystad1, M. Cancianie, P. Sestini** and G. Viegi*,## ABSTRACT: Controls for indoor air quality (IAQ) in schools are not usually performed throughout AFFILIATIONS Europe. The aim of this study was to assess the effects of IAQ on respiratory health of *Pulmonary Environmental Epidemiology Unit, CNR Institute of schoolchildren living in Norway, Sweden, Denmark, France and Italy. Clinical Physiology, Pisa, In the cross-sectional European Union-funded HESE (Health Effects of School Environment) eUdine University-Hospital Study, particulate matter with a 50% cut-off aerodynamic diameter of 10 mm (PM10) and CO2 levels ‘‘Policlinico’’, Udine, in a day of normal activity (full classroom) were related to wheezing, dry cough at night and **Siena University, Institute of Respiratory Diseases, Siena, rhinitis in 654 children (10 yrs) and to acoustic rhinometry in 193 children. ##CNR Institute of Biomedicine and -3 Schoolchildren exposed to PM10 .50 mg?m and CO2 .1,000 ppm (standards for good IAQ) Molecular Immunology ‘‘A. Monroy’’, were 78% and 66%, respectively. All disorders were more prevalent in children from poorly Palermo, Italy. #UMR-S 707, Medical School ventilated classrooms. Schoolchildren exposed to CO2 levels .1,000 ppm showed a significantly St-Antoine, University Pierre et Marie higher risk for dry cough (OR 2.99, 95% CI 1.65–5.44) and rhinitis (OR 2.07, 95% CI 1.14–3.73).
    [Show full text]